- Home
- NPV vs TIL Comparison
NPV vs TIL Comparison
Compare NPV & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPV
- TIL
- Stock Information
- Founded
- NPV 1993
- TIL 2018
- Country
- NPV United States
- TIL United States
- Employees
- NPV N/A
- TIL N/A
- Industry
- NPV Investment Managers
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- NPV Finance
- TIL Health Care
- Exchange
- NPV Nasdaq
- TIL Nasdaq
- Market Cap
- NPV 199.1M
- TIL 177.1M
- IPO Year
- NPV N/A
- TIL 2021
- Fundamental
- Price
- NPV $11.54
- TIL $21.31
- Analyst Decision
- NPV
- TIL Buy
- Analyst Count
- NPV 0
- TIL 6
- Target Price
- NPV N/A
- TIL $120.50
- AVG Volume (30 Days)
- NPV 38.9K
- TIL 145.1K
- Earning Date
- NPV 01-01-0001
- TIL 11-12-2025
- Dividend Yield
- NPV 3.90%
- TIL N/A
- EPS Growth
- NPV N/A
- TIL N/A
- EPS
- NPV N/A
- TIL N/A
- Revenue
- NPV N/A
- TIL N/A
- Revenue This Year
- NPV N/A
- TIL N/A
- Revenue Next Year
- NPV N/A
- TIL N/A
- P/E Ratio
- NPV N/A
- TIL N/A
- Revenue Growth
- NPV N/A
- TIL N/A
- 52 Week Low
- NPV $8.92
- TIL $10.80
- 52 Week High
- NPV $11.55
- TIL $73.69
- Technical
- Relative Strength Index (RSI)
- NPV 64.07
- TIL 38.07
- Support Level
- NPV $11.25
- TIL $20.11
- Resistance Level
- NPV $11.62
- TIL $25.89
- Average True Range (ATR)
- NPV 0.08
- TIL 2.57
- MACD
- NPV 0.01
- TIL -0.68
- Stochastic Oscillator
- NPV 65.91
- TIL 8.74
About NPV Nuveen Virginia Quality Municipal Income Fund
Nuveen Virginia Quality Municipal Income Fund is a diversified closed-end management investment company. The fund seeks to provide current income exempt from both regular federal and designated state income taxes. The fund invests in a portfolio of municipal obligations issued by state and local government authorities.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.